ArticleAntimicrobial agents and chemotherapy2005
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2018Pooled it
- Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.Antimicrobial agents and chemotherapy · 2020Trial
- Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment.Antibiotics (Basel, Switzerland) · 2025Article
- Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)!Antibiotics (Basel, Switzerland) · 2025Article
- Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.Biomedicines · 2021Article
- Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.Therapeutics and clinical risk management · 2021Review
- Efficacy of Dalbavancin and Telavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections.Maedica · 2018Article
- Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.Therapeutic advances in infectious disease · 2017Review
- Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Drugs · 2017Review
- Review
- Dalbavancin for the treatment of acute bacterial skin and skin structure infections.Expert opinion on pharmacotherapy · 2015Review
- Antibiotics and bacterial resistance in the 21st century.Perspectives in medicinal chemistry · 2014Review
- Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.Antimicrobial agents and chemotherapy · 2010Article
- Newer antibacterial drugs for a new century.Expert opinion on investigational drugs · 2010Review
- Review
- Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.Therapeutics and clinical risk management · 2008Article
- Current and novel antibiotics against resistant Gram-positive bacteria.Infection and drug resistance · 2008Article
- Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.P & T : a peer-reviewed journal for formulary management · 2008Article
- Dalbavancin.Drugs · 2008Review
- History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.Therapeutics and clinical risk management · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 microg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 microg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were </=4.0 microg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.